Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

ChromaTrap Helps Advance Research into Women's Reproductive Health

July 25, 2014 1:41 pm | Product Releases | Comments

An informative video interview with Professor Steve Conlan of the College of Medicine at Swansea University (UK) highlights the latest research developments in women’s reproductive health using unique molecular biology tools, and another video interview with Steve Knight of Porvair Sciences demonstrates the utility of the ChromaTrap solid state ChIP assay. Read more...

Humira Lifts AbbVie 2.8% in Q2

July 25, 2014 12:00 pm | by The Associated Press | News | Comments

Drugmaker AbbVie Inc.'s second-quarter profit increased nearly 3 percent and beat analysts' expectations, as sales soared for the world's top-selling drug, Humira. Read more...                      

TOPICS:

CHMP Recommends MA for Diabetes Drug

July 25, 2014 11:24 am | News | Comments

Novo Nordisk announced that the Committee for Medicinal Products for Human Use under the European Medicines Agency adopted a positive opinion, recommending marketing authorization for Xultophy for the treatment of type 2 diabetes mellitus in adults. Read more...

TOPICS:
Advertisement

FDA Reviews What Could Be First Biosimilar

July 25, 2014 11:20 am | News | Comments

The Food and Drug Administration is reviewing research data on what could become the first U.S.-approved "biosimilar" drug, a cheaper, sort-of generic version of a biologic drug, nearly five years after Congress passed a law enabling future approval of biosimilars. Read more...

TOPICS:

Blood Cancer Drug Gets Positive CHMP Opinion

July 25, 2014 11:09 am | News | Comments

Gilead Sciences Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company's Marketing Authorization Application for Zydelig, a first-in-class treatment for patients with chronic lymphocytic leukemia and follicular lymphoma. Read more...

TOPICS:

Genomics Reveals Mechanism for Malaria Drug Resistance

July 25, 2014 10:58 am | News | Comments

Researchers have uncovered a way the malaria parasite becomes resistant to an investigational drug, a  discovery made at Washington University School of Medicine in St. Louis that also is relevant for other infectious diseases including bacterial infections and tuberculosis. Read more...

TOPICS:

Sorafenib, Capecitabine Combo Fails to Meet Endpoint

July 25, 2014 10:49 am | News | Comments

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc., an Amgen subsidiary, announced that an investigational Phase 3 trial of sorafenib (Nexavar) tablets plus capecitabine in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival. Read more...

TOPICS:

Pfizer’s Attempted AstraZeneca Deal Gets Obama’s Attention

July 25, 2014 10:42 am | News | Comments

Staking out a populist stand ahead of the midterm elections, President Barack Obama on Thursday demanded "economic patriotism" from U.S. corporations that use legal means to avoid U.S. taxes through overseas mergers, declaring "I don't care if it's legal. It's wrong." Read more...

TOPICS:
Advertisement

Metastatic Brain Tumor Treatment Could Be on the Horizon

July 24, 2014 3:19 pm | News | Comments

Over half of patients being seen in the clinic for a diagnosed brain tumor have metastatic cancer, which has no treatment and detrimental outcomes in most cases. However, a new study provides hope that previously studied SapC-DOPS could be used for treatment of brain cancer that has spread. Read more...

TOPICS:

Researchers Create Vaccine for Dust-Mite Allergies

July 24, 2014 3:05 pm | News | Comments

If you’re allergic to dust mites (and chances are you are), help may be on the way. Researchers have developed a vaccine that can combat dust-mite allergies by naturally switching the body’s immune response. Read more...         

TOPICS:

FDA Approves Combo Painkiller from OxyContin Maker

July 24, 2014 2:59 pm | News | Comments

The Food and Drug Administration has approved a new combination pain pill from the maker of OxyContin that is designed to discourage abuse by painkiller addicts. Read more...                     

TOPICS:

Gilead Profit More Than Quadruples on Hep C Drug

July 24, 2014 2:55 pm | News | Comments

Gilead Sciences Inc. on Wednesday reported profit that more than quadrupled in its second quarter, topping analysts' expectations on sales of its new breakthrough drug for hepatitis C. Read more...                

TOPICS:

GSK Asks Europe to OK Malaria Shot

July 24, 2014 2:52 pm | News | Comments

Pharma giant GSK said Thursday it is submitting its malaria vaccine for regulatory approval to the European Medicines Agency. The experimental shot is the most advanced candidate vaccine for malaria but results from previous trials have been disappointing. Read more...

TOPICS:

EU Regulator: Morning-After Pill OK for All Women

July 24, 2014 2:48 pm | News | Comments

A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't work in women weighing more than 80 kilograms (176 pounds). Read more...

TOPICS:

Merck Kicks Off Phase 3 Study of CMV Antiviral

July 24, 2014 11:18 am | News | Comments

Merck announced that the first patient has been enrolled in a global Phase 3 clinical study that will evaluate the efficacy and safety of letermovir for the prevention of clinically-significant cytomegalovirus infection in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplants. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading